Prochymal
Prochymal® Clinical Trials for the Treatment of Acute GvHD Acute graft versus host dia (GvHD) is a potentially life threatening complication that aris in approximately 50% of all patients who receive a hematopoietic stem cell transplant (HSCT). Allogeneic HSCT are ud for the treatment of dias including hematological malignancies, certain forms of anemia, and immunological deficiencies. The transplant is derived from donated bone marrow, cord blood, or peripheral blood. GvHD occurs when immune cells in the donated cell population attack the recipient cells becau the recipient cells are en as “foreign.” Organs that are mainly affected by the immunological attack are the gastrointestinal (GI) tract, skin, and liver.
Pha 3 steroid refractory acute GvHD trial - Patient enrollment is complete.
Pha 3 newly diagnod acute GvHD trial - Patient enrollment is complete.
Pediatric Expanded Access Program - Patients are being accepted. 商品名Prochymal®的临床试验，用于治疗急性移植物抗宿主病
急性移植物抗宿主病（GVHD）是一个潜在的危及生命的并发症，出现在所有患者接受造血干细胞移植（HSCT）的约50％。异体HSCT
用于恶性血液病，某些形式的贫血和免疫缺陷的疾病，包括治疗。来自捐献骨髓，脐带血，外周血移植。移植物抗宿主发生时，免疫细胞捐赠的细胞群攻击的受体细胞的受体细胞，因为被视为“外来异物”，主要是受免疫攻击的器官的胃肠道（GI），皮肤和肝脏。
第3阶段类固醇激素难治性急性移植物抗宿主病（GVHD）试验- 病人登记完成。
第3期新诊断的急性移植物抗宿主病（GVHD）试验- 病人登记完成。
小儿扩大使用计划- 患者所接受。
体卫艺工作计划
Prochymal®Pha 3 Crohn's Dia Clinical Trial
This Trial is CuRRently enrolling patients
Crohn's dia is a chronic, life-long condition with relapsing inflammation of the bowels and gastrointestinal tract. Its fundamental cau is unknown, but it is suspected to come from a genetic predispos ition of the body’s overreaction to the environment, items in the diet, or an infection. Severe Crohn's dia can cau pain, undesirable changes in lifestyle, hospitalizations, and side-effects from medications ud for treatment. While Crohn's dia often first occurs in people between the ages of 20 and 30, it can occur in children or at any other age. In the majority of sufferer
s, it requires surgery at least
once. Over 500,000 people in the U.S. are afflicted with Crohn's dia, and approximately 20,000 new cas are diagnod each year.
The objective of the study is to establish the safety and durability of Prochymal in patients experiencing moderate-to-vere Crohn’s dia who are refractory to steroid, immunosuppressant, and biologic therapy.
餐饮英文商品名Prochymal®第3期克罗恩病的临床试验
这项试验是目前正在招募患者
汪立群克罗恩病是一种慢性，终身的条件，肠子和胃肠道炎症的复发。其根本原因是未知的，但它被怀疑来自身体的过度反应的遗传易感性，环境，饮食中的项目，或感染。重度克罗恩病可以引起疼痛，不良生活方式的改变，住院，药物用于治疗和副作用。虽然克罗恩病往往首先发生在20至30岁之间的人，它可以发生于儿童或在任何其他年龄段。在大多数的患者，需要手术治疗至少一次。在美国，超过50万人患有克罗恩病，每年约20,000个新病例被确诊。
这项研究的目的是要建立在患者出现中度至重度克罗恩病是难治性类固醇，免疫抑制剂，生物治疗的
马桶的疏通安全性和耐用性商品名Prochymal。
Hearticellgram-AMI
Hemacord
HEMACORD (hematopoietic progenitor cells, cord blood)
STN: BL 125397/0
小帅影院
Proper Name: Hematopoietic progenitor cells, cord blood
Trade Name: Hemacord
Manufacture: New York Blood Center, Inc
Indication: For u in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.
HEMACORD（造血祖细胞，脐带血）
STN：BL125397/0
正确的名称：脐带血造血祖细胞，
巍峨的读音
商品名称：Hemacord
制造商：纽约血液中心，公司
适应症：对于无关供者造血干细胞移植程序，结合适当的预处理方案
的造血和免疫重建的影响造血系统的继承，收购，或清髓性治疗的结果与疾病的患者使用。
WARNING: FATAL INFUSION REACTIONS, GRAFT VERSUS HOST DISEASE, ENGRAFTMENT SYNDROME, AND GRAFT FAILURE
See full prescribing information for complete boxed warning.
大班科学领域目标Fatal infusion reactions: Monitor patients during infusion and discontinue for vere reactions. U is contraindicated in patients with known allergy to dimethyl sulfoxide (DMSO), Dextran 40 or human s
erum albumin. (4, 5.1, 5.2)
• Allergic Reactions and Anaphylaxis (5.1)
• Infusion Reactions (5.2)
• Graft-versus-Host Dia (5.3)
Graft-vs-host dia (GVHD): GVHD may be fatal. Administration of immunosuppressive therapy may decrea the risk of GVHD. (5.3)
鸡头的做法
Engraftment syndrome: Engraftment syndrome may be fatal. Treat engraftment syndrome promptly with corticosteroids. (5.4) Graft failure: Graft failure may be fatal. Monitor patients for laboratory evidence of hematopoietic recovery.
警告：严重的输液反应，移植物抗宿主病，移植物植入综合征，移植
